Trial Profile
A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week treatment period as add-on to 10 mg donepezil once daily in patients with mild to moderate dementia of the Alzheimer's type.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Tesofensine (Primary) ; Donepezil
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 Dec 2021 This trial has been completed in Czech republic (Global end date: 18 Mar 2005).
- 03 Jun 2011 New trial record